Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Novita Healthcare’s attention treatment program will soon be delivered through the U.S. Reimbursement Code system
  • TALi Train is a training game for children with attention disorders
  • The TALi technology will now target eight million children in the U.S. currently diagnosed with ADHD or autism
  • Further news on any potential partners, customers, and the launch of TALi will be given in the coming quarters
  • Novita Healthcare is up 17.2 per cent today, with shares trading for 6.8 cents each

Novita Healthcare’s FDA-cleared TALi Train, a digital attention treatment program, will be delivered through the U.S. Reimbursement Code system.

The Australian meditech company developed TALi Train as a game-based training program for young children. It was designed by neuroscientists at Monash University who recognised the lack of treatment and learning options for children with neurodevelopment disorders.

The program enables children to focus on tasks and concentrate on learning at school. It also teaches children to avoid fidgeting, prevent impulsive behaviour, and avoid distractions.

Managing Director Glenn Smith is pleased that TALi is being recognised as a new, scalable, and effective technology for assessment and treatment of attention.

“TALi Train is currently the only regulatory cleared early childhood digital cognitive assessment and training program and with all development and compliance requirements achieved we are now set to execute on our go-to-market strategy to realise the potential of this world-leading technology,” Glenn said.

The CPT ( Current Procedural Terminology) Codes offer health care professionals a uniform language for coding medical services and procedures.

They are also used to manage claims processing and developing guidelines for medical review.

This development allows for patient reimbursement for TALi Train under relevant U.S. codes.

TALi Train will be used as an alternate treatment option targeting over eight million children in the U.S. currently diagnosed with ADHD or autism.

Novita will provide further guidance on the deployment and billing schedule for its TALi technology. It will also continue to work with physicians, customers, and any potential partners during the launch over the coming quarters.

Novita Healthcare is up 17.2 per cent today, with shares trading for 6.8 cents at 11:27 am AEDT.

NHL by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.